CAMBRIDGE, Mass., Sep 13, 2010 (BUSINESS WIRE) -- Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) announced it will host a
conference call and webcast today at 6:00 p.m. Eastern Time to discuss
the positive top-line results of its Phase 3 clinical trial of
linaclotide in patients with irritable bowel syndrome with constipation
(IBS-C). Individuals interested in participating in the call should dial
(888) 215-6825 (U.S. and Canada) or (913) 312-0844 (international) using
conference ID number 4215125. To access the webcast, please visit the
Investors section of Ironwood's website at www.ironwoodpharma.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required. The call will be
available for replay via telephone starting September 13, 2010 at 9:00
p.m. Eastern Time, running through 11:59 p.m. Eastern Time on September
27, 2010. To listen to the replay, dial (888) 203-1112 (U.S. and Canada)
or (719) 457-0820 (international) using conference ID number 4215125. An
archived version of the event will be available on Ironwood's website
for 14 days beginning approximately one hour after the call.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial
pharmaceutical company dedicated to the art and science of great
drugmaking. Linaclotide, Ironwood's GC-C agonist, is being evaluated in
a confirmatory Phase 3 program for the treatment of irritable bowel
syndrome with constipation (IBS-C) and chronic constipation. Ironwood
also has a growing pipeline of additional drug candidates in earlier
stages of development. Ironwood is located in Cambridge, Mass.
SOURCE: Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Susan Brady, 617-621-8304
Corporate Communications
sbrady@ironwoodpharma.com
Copyright Business Wire 2010